|1.||Vesely, David L: 11 articles (01/2011 - 01/2005)|
|2.||Weiss, Harvey R: 10 articles (01/2009 - 08/2002)|
|3.||Scholz, Peter M: 9 articles (01/2009 - 08/2002)|
|4.||Felipo, Vicente: 8 articles (04/2013 - 08/2005)|
|5.||Eichelbaum, Ehrentraud J: 7 articles (06/2009 - 09/2006)|
|6.||Sun, Ying: 7 articles (06/2009 - 09/2006)|
|7.||Wang, Hai: 6 articles (06/2009 - 09/2006)|
|8.||Zhang, Qihang: 6 articles (01/2009 - 08/2004)|
|9.||Chen, Zhijian J: 5 articles (10/2015 - 02/2013)|
|10.||Azuma, Hiroshi: 5 articles (09/2008 - 02/2005)|
06/01/2007 - "Erectile dysfunction (ED) is caused by a variety of pathogenic factors, particularly impaired formation and action of NO. Hence, a thorough knowledge of the physiology of erection is essential for future pharmacological innovations in the field of male ED, particularly targeting NO or intracellular cyclic GMP, which represent the most promising therapeutic approach to treat patients with ED."
05/01/2005 - "Erectile dysfunction (ED) is caused by a variety of pathogenic factors, particularly impaired formation and action of NO. Thus, replenishment of this molecule or intracellular cyclic GMP is expected so far to be the most promising therapeutic measures for patients with ED. "
04/01/1995 - "Relaxant response, NO formation and cyclic GMP formation in tissue from men with non-vascular impotence was similar to controls. "
03/01/1993 - "Intracavernous cyclic GMP produces penile erection in patients with erectile dysfunction."
09/01/2002 - "Sildenafil is a potent and selective inhibitor of the cyclic GMP-specific phosphodiesterase (PDE5) that is very effective in the treatment of male impotence. "
12/01/2014 - "We propose that sGC and cyclic GMP function as tumor suppressors. "
05/01/2003 - "Immunohistochemistry was used to determine cyclic GMP (cGMP) phosphodiesterase (PDE) expression in tumors. "
03/01/2003 - "iNOS activity and cyclic GMP production were significantly higher in the cancer specimens than in the normal mucosa (P < 0.0001 and P < 0.0001, respectively), as well as in metastatic tumors than in nonmetastatic ones (P = 0.002 and P = 0.04, respectively). "
07/01/1989 - "In contrast, in the homogeneous population of tumor corticotrophs AtT-20, there was a close relationship between cyclic GMP formation and cell density. "
02/01/1984 - "Incubation of normal blood lymphocytes with cyclic GMP induced an abnormal, cancer-like FFP response."
|3.||Cardiomegaly (Heart Hypertrophy)
12/01/2011 - "Intracellular cyclic GMP is a second messenger that modulates: platelet aggregation, neurotransmission, sexual arousal, gut peristalsis, blood pressure, long bone growth, intestinal fluid secretion, lipolysis, phototransduction, cardiac hypertrophy and oocyte maturation. "
01/01/2009 - "The effects of cyclic GMP are blunted in cardiac hypertrophy. "
02/01/2005 - "Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy."
07/01/1998 - "This suggested that the reduction in myocardial O2 consumption, related to increases in cyclic GMP caused by cyclic GMP-phosphodiesterase blockade, was less in 1K1C cardiac hypertrophy."
07/01/1998 - "Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy."
05/26/1977 - "Changes in the cyclic GMP-dependent enzyme activity appeared to precede gross atrophy or hypertrophy of the vessels. "
06/01/2002 - "The aim of the study was to develop an improved test to detect the codon 616 gene mutation in the alpha cyclic GMP phosphodiesterase gene that causes progressive retinal atrophy in the Cardigan Welsh Corgi. "
06/01/2002 - "An improved DNA-based test for detection of the codon 616 mutation in the alpha cyclic GMP phosphodiesterase gene that causes progressive retinal atrophy in the Cardigan Welsh Corgi has been designed. "
06/01/2002 - "An improved DNA-based test for detection of the codon 616 mutation in the alpha cyclic GMP phosphodiesterase gene that causes progressive retinal atrophy in the Cardigan Welsh Corgi."
06/01/1987 - "To examine the interrelationship between human atrial natriuretic polypeptide (hANP) and cyclic 3'5'-guanosine monophosphate (cyclic GMP), plasma concentrations of these compounds were determined in 61 disease-free humans, as controls, and in 35 patients with congestive heart failure. "
05/01/2006 - "These insights, which challenge classically held views that NO acts as a freely diffusible molecule regulated primarily by concentration and exerting signaling primarily through cyclic GMP production, offer a new perspective on the pathophysiology and treatment of congestive heart failure."
09/01/1999 - "Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction."
08/01/1993 - "3. The pericardial fluid concentration of cyclic GMP, the intracellular second messenger for atrial natriuretic peptide, was significantly higher in patients with congestive heart failure than in patients without heart failure."
04/01/1992 - "It may be related to an abnormality situated after the receptor and second messenger, cyclic GMP and/or the reduction of renal perfusion pressure which occurs in cardiac failure. "
|1.||Nitric Oxide (Nitrogen Monoxide)
|2.||Cyclic AMP (AMP, Cyclic)
|3.||Guanylate Cyclase (Guanylyl Cyclase)
|4.||DNA (Deoxyribonucleic Acid)
|5.||Type 5 Cyclic Nucleotide Phosphodiesterases
|9.||Peptide Receptors (Peptide Receptor)
|1.||Surgical Instruments (Clip)
|3.||Homologous Transplantation (Allograft)
|4.||Renal Dialysis (Hemodialysis)